Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Apranga nine-month 2026 pretax profit rises 30% to EUR 19.2 million

Apranga nine-month 2026 pretax profit rises 30% to EUR 19.2 million

BitgetBitget2026/10/29 14:00
  • Apranga’s unaudited consolidated pretax profit rose 30% year over year to EUR 19.2 million in the first nine months of 2026.
  • EBITDA climbed 14% year over year to EUR 36.5 million.
  • Retail turnover including VAT increased 9% year over year to EUR 290.8 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. APB Apranga published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610291000OMX_____CNEWS_EN_GNW1001280617_en) on October 29, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

The 160 Threshold Under Threat Again! Yen Nears "Intervention Red Line," Tokyo May Spend Money Again to Rescue the Currency

The Japanese yen is approaching the 1 USD = 160 JPY level. Atsushi Mimura commented that the movement is "too fast." The US-Japan interest rate gap may widen further, and Japanese officials have hinted at being ready to intervene again.

智通财经•2026/11/12 02:26

Blackstone (BX.US) injects up to $1.5 billion, providing fresh ammunition for Pfizer (PFE.US) in the weight-loss drug race

Pfizer announced on Wednesday that it has reached an agreement with Blackstone to obtain up to $1.5 billions in funding to support the development of its experimental monthly obesity treatment drug.

智通财经•2026/11/12 01:07